grant

DNA induction of neutrophilic asthma

Organization NATIONAL JEWISH HEALTHLocation DENVER, UNITED STATESPosted 17 Sept 2021Deadline 31 Aug 2026
NIHUS FederalResearch GrantFY2025(TNF)-αAbbreviationsAbscissionAdaptor ProteinAdaptor Protein GeneAdaptor Signaling ProteinAdaptor Signaling Protein GeneAdjuvantAgreementAirway Hyper-responsivenessAllergensAllergic asthmaAlternariaAluminum HydroxideAlveolar MacrophagesAnti-InflammatoriesAnti-Inflammatory AgentsAnti-inflammatoryAsthmaBiopsy SampleBiopsy SpecimenBlood NeutrophilBlood Polymorphonuclear NeutrophilBlood SerumBlood donorBlood monocyteBronchial AsthmaBronchioalveolar LavageBronchoalveolar LavageBronchopulmonary LavageCD134LCSIFCSIF-10CachectinCadaverCell BodyCell Communication and SignalingCell SignalingCellsChemotactic CytokinesCo-StimulatorConfocal MicroscopyCostimulatorCytokine Synthesis Inhibitory FactorDNADNA NucleasesDNaseDataDeoxyribonucleasesDeoxyribonucleic AcidDevelopmentEpidermal Thymocyte Activating FactorEpithelial CellsExcisionExtirpationExtracellular FluidExtrinsic asthmaFamilyFc ReceptorFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryGP34GenerationsHomologous Chemotactic CytokinesHumanHydrated AluminaIFNIFN activationIFN-GammaIFN-gIFN-γIFNGIFNγIL-10IL-10 receptorIL-2IL10IL10AIL2 ProteinImmune InterferonImmunofluorescenceImmunofluorescence ImmunologicInfectionInflammasomeInflammationInflammatoryIntercrinesInterferon ActivationInterferon GammaInterferon Type IInterferon Type IIInterferonsInterleukin 10 PrecursorInterleukin 2Interleukin 2 PrecursorInterleukin IIInterleukin-10Interleukin-2Interleukine 2Interleukine 2 PrecursorInterleukine IIIntracellular Communication and SignalingKO miceKnock-out MiceKnockout MiceLipofectamineLungLung LavageLung Respiratory SystemLymphocyte Mitogenic FactorMacrophageMacrophage-Derived TNFMarrow NeutrophilMarrow monocyteMediatingMiceMice MammalsMitogenic FactorModelingModern ManMolecularMonocyte-Derived TNFMurineMusNasal Lavage FluidNasal WashingNasal WashingsNeutrophilic GranulocyteNeutrophilic LeukocyteNucleosomesNull MouseOX40LOrthologOrthologous GeneOutcomePBMCPathologic ProcessesPathological ProcessesPathologyPathway interactionsPatternPeripheral Blood Mononuclear CellPhenotypePolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsProteinsPulmonary MacrophagesRefractoryRemovalRhinovirusRoleSIS cytokinesSTING1 geneSerumSignal TransductionSignal Transduction SystemsSignalingSputumStaining methodStainsStimulator of Interferon GenesSurgical RemovalT cell growth factorT-Cell Growth FactorT-Cell Stimulating FactorTMEM173TNFTNF ATNF AlphaTNF geneTNF-αTNFATNFSF4TNFSF4 geneTNFαTXGP1TherapeuticThymocyte Stimulating FactorTumor Necrosis FactorTumor Necrosis Factor-alphaVirusadapter proteinairway epithelium inflammationairway hyper-reactivityairway hyperactivityairway hyperreactivityairway hyperresponsivenessairway hypersensitivityairway inflammationantibody receptorasthma attackasthma exacerbationasthma modelasthma patientasthmatic patientatopic asthmabiological signal transductionbronchial epitheliumbronchiolar alveolar lavagebronchopulmonary lavage therapycGAMP STINGcGAMP-STINGcGAMP/STINGcGAS/STINGcadavericcadaverschemoattractant cytokinechemokinecyclic GMP-AMP synthase/STINGcytokinedevelopmentaldisease controldisorder controleffective therapyeffective treatmenteosinophilic inflammationexacerbation in asthmaexacerbation prone asthmaexacerbation prone asthmaticextracellularextrinsic allergic asthmaflow cytophotometryhuman DNAinhibitorinterleukin-10 receptorlFN-Gammamonocytemouse modelmurine modelneutrophilnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic targetnew therapeuticsnew therapynew therapy targetnext generation therapeuticsnovelnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy targetpathwaypatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypesperipheral bloodpre-clinical studypreclinical studyprogramsresectionresident memory T cellrespiratory inflammationrespiratory tract inflammationsensorsocial roletargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic evaluationtherapeutic testingtissue resident memory T celltranscriptomics
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY
Neutrophilic asthma is a subtype of severe asthma, which has no safe and effective therapy. There is an

unmet need to delineate the mechanism of neutrophilic asthma and develop targeted and effective therapies.

Host cell-derived DNA is present in the extracellular fluid and serum. DNA represents a danger signal (danger-

associate molecular pattern-DAMP) for host cells. Recent studies suggest an important role for extracellular

DNA in mediating virus-induced asthma exacerbation. We present robust preliminary data demonstrating

increased levels of extracellular DNA, the DNA sensor IFI16 (Interferon-gamma induced protein-16) and the

DNA-IFI16 pathway-driven cytokines/chemokines in the airways from neutrophilic asthma. We developed a

mouse model of asthma where DNA induces neutrophilic inflammation in the context of an IL10-constrained

inflamed airway milieu. This phenotype requires the participation of the IFI16 signaling adapter STING. Based

upon these novel preliminary results we hypothesize that extracellular DNA induces neutrophilic asthma

through the IFI16-STING pathway in the presence of select IL10-suppressive TNFSFs. Neutrophil extracellular

traps generate DNA, which establishes a self-perpetuated mechanism of neutrophilic asthma. Under Aim 1 we

will examine the relevance of extracellular DNA for human neutrophilic asthma. We will study the generation of

airway extracellular DNA, activation of IFI16 and IL10-suppressive TNFSFs—TNF and OX40L and their

pathophysiological consequences in the airways. We will study bronchoalveolar lavage (BAL), bronchial

epithelial cells and biopsy specimens from 3 study groups: 1) Neutrophilic (with and without eosinophilic)

asthma; 2) Non-neutrophilic (with and without eosinophilic) asthma; and 3) Disease controls. We will delineate

the function and importance of IFI16 for proneutrophilic biomolecules in a reductionist model in DNA-treated

airway macrophages and blood monocytes. Under Aim 2 we will study the mechanism of extracellular DNA-

induced neutrophilic asthma in mice. We will elucidate the role of IL10 and TNFSFs (TNF and OX40L) in

switching the DNA-induced defensive program to a neutrophilic inflammation program in mouse airways. We

will establish the role of IFI204 (the mouse IFI16 ortholog) and STING in neutrophilic inflammation. We will

study the effect of removal of extracellular DNA on persistence of neutrophilic asthma in mice. This project is

important because it uncovers a novel DNA-IFI16-STING mechanism of neutrophilic asthma and assesses the

therapeutic benefits of DNA and STING inhibitors, and DNA scavengers in a preclinical study.

Grant Number: 5R01AI165922-05
NIH Institute/Center: NIH

Principal Investigator: Rafeul Alam

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →